ArticleVox sanguinis2026
Autoantibodies in COVID-19 convalescent plasma donors.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Viral Immunity in Immunoglobulin Products: Global Immunity Debt and Autoimmunity in the Postpandemic Era.European journal of immunology · 2026Article
- Autoantibodies in COVID-19 convalescent plasma donors.Vox sanguinis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesAlthough COVID-19 convalescent plasma (CCP) has been successfully used to treat several viral infections, its effectiveness in neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its broader immunological safety remain debated. Since viral infections can trigger autoimmunity, particularly through molecular mimicry and immune dysregulation, there is growing interest in understanding whether CCP contains autoantibodies that could affect recipient safety. MATERIALS AND
methodsIn this study, we evaluated the presence of 20 different autoantibodies, along with anti-SARS-CoV-2 antibodies, in plasma samples from CCP donors. Samples were collected at three time intervals following COVID-19 symptom onset: 0-60, 60-120 and 120-180 days. Results were compared with those from healthy control plasma donors.
resultsSeveral autoantibodies- anti-Smith (anti-SM), anti-Sjögren syndrome antigen A, 60-kDa isoform (anti-SSA/Ro60), anti-proliferating cell nuclear antigen (anti-PCNA), anti-Ribosomal P and anti-ribonucleoprotein/Smith antigen complex (anti-RNP/SM)-showed modestly elevated levels in CCP samples collected within 0-60 days post symptom onset. In the 60-120-day period, autoantibody levels declined and approached levels observed in the control group. In the 120-180-day period, most autoantibody levels remained comparable to control levels. Our analysis showed no significant correlations between levels of neutralizing SARS-CoV-2 antibodies and autoantibody concentrations nor significant differences in autoantibody profiles between donors with high and low neutralizing antibody (NAb) titres.
conclusionOur findings suggest that SARS-CoV-2 infection may transiently elevate certain autoantibodies in CCP donors. However, most autoantibody levels decline over time and the overall profiles do not indicate sustained autoreactivity. These results support the immunological safety of CCP, particularly when collected between 60 and 120 days post infection, and highlight the importance of timing in optimizing both efficacy and safety in plasma donation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.